MetriCide™ OPA Plus Solution Test Strip

K241344 · Steris · JOJ · Jun 11, 2024 · General Hospital

Device Facts

• Record ID: K241344
• Device Name: MetriCide™ OPA Plus Solution Test Strip
• Applicant: Steris
• Product Code: JOJ · General Hospital
• Decision Date: Jun 11, 2024
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 880.2800
• Device Class: Class 2

Indications for Use

MetriCide OPA Plus Solution Test Strips are chemical indicators for use in determining whether the concentration of ortho-phthalaldehyde, the active ingredient in MetriCide OPA Plus Solution, is above or below the Minimum Recommended Concentration (MRC) of 0.3% established for MetriCide OPA Plus Solution.

Device Story

MetriCide OPA Plus Solution Test Strip is a chemical indicator used to verify the concentration of ortho-phthalaldehyde (OPA) in high-level disinfectant solutions. The device consists of an absorbent paper pad impregnated with an indicator reagent, affixed to a polymer substrate handle. Operation involves immersing the strip in the OPA solution for 1 second, then observing the color change of the pad after 90 seconds. A color shift from light blue to purple indicates the concentration status relative to the 0.3% MRC. The device is used in clinical or reprocessing environments to ensure disinfectant efficacy. Healthcare personnel visually interpret the color change to determine if the solution is suitable for use, thereby ensuring proper disinfection of medical instruments and patient safety.

Clinical Evidence

Bench testing only. Performance characterization demonstrated >80% pass rate for 0.45% OPA solution and 0% pass rate for 0.3% OPA solution. Analytic specificity and contaminant testing confirmed 0% pass rate for tap water and contaminated 0.3% OPA solutions, respectively. Shelf life testing was successfully completed.

Technological Characteristics

Absorbent paper pad impregnated with indicator reagent; affixed to inert polypropylene film substrate. Colorimetric sensing principle (light blue to purple). Manual visual read. 90-second read time. No electronic components or software.

Indications for Use

Indicated for use as a chemical indicator to determine if the concentration of ortho-phthalaldehyde in MetriCide OPA Plus Solution is above or below the 0.3% Minimum Recommended Concentration (MRC).

Regulatory Classification

Identification

Biological sterilization process indicator: A device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor adequacy of sterilization. The device consists of a known number of microorganisms, of known resistance to the mode of sterilization, in or on a carrier and enclosed in a protective package. Subsequent growth or failure of the microorganisms to grow under suitable conditions indicates the adequacy of sterilization. Physical/chemical sterilization process indicator: A device intended for use by a health care provider to accompany products being sterilized through a sterilization procedure and to monitor one or more parameters of the sterilization process. The adequacy of the sterilization conditions as measured by these parameters is indicated by a visible change in the device.

Predicate Devices

• Browne OPA Test Strip (K081427)

Reference Devices

• K991709

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is a symbol representing the Department of Health & Human Services - USA. To the right of this symbol, there is a blue square with the letters "FDA" in white. Next to the blue square, the words "U.S. FOOD & DRUG ADMINISTRATION" are written in blue.

June 11, 2024

STERIS Corporation Anthony Piotrkowski Director, Regulatory Affairs 5960 Heisley Rd Mentor. Ohio 44060

Re: K241344

Trade/Device Name: MetriCide™ OPA Plus Solution Test Strip Regulation Number: 21 CFR 880.2800 Regulation Name: Sterilization Process Indicator Regulatory Class: Class II Product Code: JOJ Dated: May 13, 2024 Received: May 13, 2024

Dear Anthony Piotrkowski:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

> Sincerely, Digitally signed by Stephen Stephen A. A. Anisko -S Anisko -S Date: 2024.06.11 13:22:36 -04'00 for: Christopher Dugard Assistant Director DHT4B: Division of Infection Control and Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality

Center for Devices and Radiological Health

{2}------------------------------------------------

Enclosure

{3}------------------------------------------------

### Indications for Use

510(k) Number (if known) K241344

Device Name

MetriCide™ OPA Plus Solution Test Strip

### Indications for Use (Describe)

MetriCide OPA Plus Solution Test Strips are chemical indicators for use in determining whether the concentration of ortho-phthalaldehyde, the active ingredient in MetriCide OPA Plus Solution, is above or below the Minimum Recommended Concentration (MRC) of 0.3% established for MetriCide OPA Plus Solution.

| Type of Use (Select one or both, as applicable) | <table style="border:none;"><tr><td><input type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D)</td></tr><tr><td><input checked="" type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C)</td></tr></table> | <input type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) | <input checked="" type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------|
| <input type="checkbox"/> Prescription Use (Part 21 CFR 801 Subpart D) | | | |
| <input checked="" type="checkbox"/> Over-The-Counter Use (21 CFR 801 Subpart C) | | | |

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

***DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

PRAStaff(@fda.hhs.qov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Paperwork Reduction Act (PRA) Staff

FORM FDA 3881 (8/23)

Page 1 of 1

PSC Publishing Services [phone] EF

{4}------------------------------------------------

# K241344 510(k) Summary For MetriCide™ OPA Plus Solution Test Strip

### Sponsor Facility

STERIS Corporation 5960 Heisley Road Mentor, OH 44060 Phone: [phone] Fax No: [phone]

### Manufacturing Facility

Contact:

Anthony Piotrkowski Director, Regulatory Affairs Telephone: [phone] Fax No: [phone] Tony [e-mail]

May 13, 2024 Submission Date:

STERIS Corporation ■ 5960 Heisley Road ■ Mentor, OH 44060-1834 USA ■ 440-354-2600

{5}------------------------------------------------

#### 1. Predicate Device

Trade Name: Common/Usual Name: Classification: Classification Name: 510(k) Submitter/Holder: 510(k) Number:

Browne OPA Test Strip Chemical Indicator Class II Physical/chemical Sterilization Process Indicator STERIS Corporation K081427

#### 2. Device Description

The MetriCide™ OPA Plus Solution Test Strip is for use with MetriCide™ OPA Plus ortho-Phthaldehyde (OPA) High Level Disinfectant (HLD) solution which contains 0.6% MetriCide™ as the active ingredient. The test strip is an OPA concentration indicator that was developed for another OPA HLD solution. The test strip consists of an impregnated paper pad attached to a polymer substrate (which serves as the handle) - the test strip is evaluated by looking at the color of the pad at the stated read time. In essence, the test strip, following immersion in the test solution for a specified time period (1 second), will change from a start color to an endpoint color in a manner that is dependent on the concentration of the active (OPA); the test strip is read at a specified time interval (90 seconds).

#### 3. Indications for Use:

MetriCide OPA Plus Solution Test Strips are chemical indicators for use in determining whether the concentration of ortho-phthalaldehyde, the active ingredient in MetriCide OPA Plus Solution, is above or below the Minimum Recommended Concentration (MRC) of 0.3% established for MetriCide OPA Plus Solution.

#### 4. Technological Characteristics

There have been no physical modifications to the subject device K241344 compared to the predicated device K081427. The mechanism of action and endpoint are the same and when exposed to the defined processing conditions, the proposed and predicate devices the same visible color change.

Note that the predicate for K081427 was K991709 where K081427 had no physical modifications from K991709: and K081427 was submitted and cleared to support a 60 second read time for K081427 compared to the 90 second read time for K991709.

{6}------------------------------------------------

| Feature | Proposed: MetriCide™ OPA Plus Solution<br>Test Strip | Predicate: Browne OPA Test Strip<br>(K081427) | Comparison |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Intended Use /<br>Indications for<br>Use | MetriCide OPA Plus Solution Test Strips are<br>chemical indicators for use in determining<br>whether the concentration of ortho-<br>phthalaldehyde, the active ingredient in<br>MetriCide OPA Plus Solution, is above or below<br>the Minimum Recommended Concentration<br>(MRC) of 0. 3 % established for<br>MetriCide OPA Plus<br>Solution. | The Browne OPA Test Strip is a concentration<br>monitor for use in ortho-phthalaldehyde<br>containing germicide solutions with a<br>minimum effective concentration of 0.3%.<br>The Browne OPA Test Strip is dedicated for<br>use with CidexTM OPA solution | Similar - both<br>products monitor<br>OPA at an MEC or<br>MRC of 0.3% |
| Dip and Read<br>Time | 1 second, 90 seconds | 1 second, 60 seconds | Similar |
| Device Design<br>- components | Absorbent paper impregnated with<br>indicator solution affixed to inert<br>polypropylene film | Absorbent paper impregnated with<br>indicator solution affixed to inert<br>polypropylene film | Identical |
| Shelf Life | 11 months | 10 months | Similar |
| Color change | Light blue to purple | Light blue to purple | Identical |

## Table 1 Comparison of CI Physical Description and Technological Properties

The only changes to the subject device K241344 compared to the predicate device K081427 are the indication for use in another brand of OPA and the consequent labeling changes, and the difference in read times. Since the 90 second read time was established for the same physical product in K991709, and the testing to support subject device K241344 was performed with a 90 second read time, the 90 second read time is acceptable for the subject device. Although the indications are changing, the intended use, to monitor OPA at an MEC or MRC of 0.3%, remains the same.

#### న్. Performance Testing

Performance testing was completed using well established methods, i.e. those used to verify the predicate design.

| Testing | Acceptance Criteria | Study Result |
|---------------------------------|------------------------------------------------------------------------------------------|-------------------------|
| Performance<br>Characterization | - Minimum 80% PASS results for strips tested with 0.45%<br>MetriCideTM OPA Plus solution | Pass – All criteria met |
| Shelf Life | - 0% PASS results for strips tested with 0.3% MetriCideTM OPA<br>Plus solution | Pass – All criteria met |
| Analytic Specificity | 0% PASS results for strips exposed to tap water | Pass - Criterion met |
| Contaminants Testing | 0% PASS results for strips tested with contaminated 0.3%<br>MetricideTM OPA solutions. | Pass - Criterion met |

### Table 2. Verification Results Summary

The results of the performed testing demonstrate that the MetriCide™ OPA Plus Solution Test Strip performs as intended.

{7}------------------------------------------------

#### 6. Conclusion

The conclusion drawn from the non-clinical testing demonstrates that the subject device, MetriCide™ OPA Plus Solution Test Strip, is as safe, as effective, and performs as well as the legally marketed predicate device, Browne OPA Test Strip, cleared under K081427.